We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / CNS PHARMACEUTICALS
CNS_PHARMA_METAS_SERVICE_ALT

CNS PHARMACEUTICALS

Lesvi offers one of the most comprehensive product portfolios in CNS pharmaceuticals.
1234
Product Indication Dosage form Strength
Piracetam Alzheimer Solution for injection 200mg/ ml
Pramipexol Parkinson's IR tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Pregabaline * Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Promethazine Agitation and restlessness Injection 25mg/ ml
Promethazine Agitation and restlessness Oral solution 20mg/ ml
100mg/ ml
Pyridostigmine Myasthenia gravis Film-coated tablets 60 mg
Pyridostigminie Myasthenia gravis XR tablets 180 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Rasagiline (tartrate) Parkinson's Tablets 1 mg
Risperidone Psychosis, schizophrenia, bipolar disoder Film-coated tablets 1, 3 and 6 mg
Rotigotine Parkinson disease & restless legs Patches 1, 2, 3, 4, 6 and 8 mg/24h
Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Sulpiride Psychosis, schizophrenia Tablets 50 and 200 mg
Sultiame * Epilepsy, convulsions Film-coated tablets 50, 100 and 200 mg
Tolcapone Parkinson's Film-coated tablets 100 mg
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
Trazodone Depression XR tablets 75 and 150 mg
Trimipramine Depression Oral drops, solution 40mg / ml
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.